Pharmacotherapy to Manage Central Post-Stroke Pain

Area of Science:

• Neurology
• Pain Medicine
• Stroke Rehabilitation

Background:

• Central post-stroke pain (CPSP) is a chronic neuropathic pain syndrome following cerebrovascular accidents.
• CPSP affects an estimated 8-55% of stroke patients, presenting as constant or intermittent pain with sensory deficits in the lesioned area.
• Diagnosis is challenging due to diverse clinical presentations and its nature as a diagnosis of exclusion.

Purpose of the Study:

• To review the clinical presentation, diagnosis, and treatment of central post-stroke pain.
• To establish a therapeutic algorithm for managing this challenging condition.
• To explore pharmacologic and interventional treatment options for CPSP.

Main Methods:

• Literature review of existing evidence on central post-stroke pain.
• Analysis of pharmacologic and interventional treatment strategies.
• Synthesis of diagnostic criteria and therapeutic recommendations.

Main Results:

• CPSP is characterized by neuropathic pain and sensory disturbances correlating with stroke lesion location.
• Onset can be gradual, immediate, or delayed years after the stroke.
• Pharmacological options include first-line treatments like amitriptyline, lamotrigine, and gabapentinoids, with other agents for intractable cases.

Conclusions:

• Central post-stroke pain presents a diagnostic and therapeutic challenge due to its varied presentation and resistance to treatment.
• First-line pharmacotherapy should include amitriptyline, lamotrigine, and gabapentinoids.
• Interventional therapies like motor cortex stimulation and transcranial magnetic stimulation offer relief for difficult-to-treat patients.